ABIVAX

Profil de la société

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Description disponible en anglais.

Informations sur la société

Secteur

Santé

Industrie

Biotechnology

Pays

France

Siège

7-11 Boulevard Haussmann, 75009, Paris

Salariés

98

Cotation

ABVX · Euronext Paris

Devise

EUR

ISIN

FR0012333284

Site web

abivax.com